aida network still disease registry (Disease Registry)
86
Structured Review
Disease Registry
aida network still disease registry
Aida Network Still Disease Registry, supplied by Disease Registry, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aida+network+still+disease+registry/aida+beh%C3%A7et+disease+international+network+registry+s/pm40516928-389-24-27
Average 86 stars, based on 1 article reviews
Aida Network Still Disease Registry, supplied by Disease Registry, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aida+network+still+disease+registry/aida+beh%C3%A7et+disease+international+network+registry+s/pm40516928-389-24-27
Average 86 stars, based on 1 article reviews
aida network still disease registry - by Bioz Stars,
2026-09
86/100 stars
Images
Related Articles
Biomarker Discovery:Article Title: First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study Article Snippet: .. 10 Ruscitti P, Masedu F, Vitale A, et al. Derivation and validation of four patient clusters in Still’s disease, results from GIRRCS AOSDstudy group and Article Title: Serum cytokine levels towards precision medicine in Still's disease: a subanalysis of a randomized controlled trial of tocilizumab. Article Snippet: Objectives: To predict the efficacy of IL-6 inhibition in patients with Still’s disease by analysing inflammatory cytokine profiles before and during an IL-6 receptor inhibitor therapy.. Methods: This is a subanalysis of the 52-week, randomized, double-blind, placebo-controlled trial of tocilizumab, an IL-6 receptor inhibitor, in patients with Still’s disease.. Multiple serum cytokine levels were measured regularly, and their pattern and profiles were analysed based on the response to tocilizumab. Article Title: Derivation and validation of four patient clusters in Still's disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry. Article Snippet: .. Piero Ruscitti , Francesco Masedu, Antonio Vitale, Ilenia Di Cola, Valeria Caggiano, Claudia Di Muzio, Paola Cipriani, Marco Valenti, Onorina Berardicurti, Luca Navarini, Daniela Iacono, Ilenia Pantano, Daniele Mauro, Francesco Ciccia , Silvia Rossi, Ludovico De Stefano , Sara Monti , Serena Bugatti , Carlomaurizio Montecucco, Francesco Caso , Luisa Costa, Marcella Prete, Federico Perosa, Annamaria Iagnocco, Fabiola Atzeni, Giuliana Guggino , Henrique Giardini , Isabele Parente de Brito Antonelli, Ibrahim A Almaghlouth, Kazi Asfina , Haner Direskeneli , Fatma AlibazOner , Gizem Sevik, Abdurrahman Tufan , Petros P Sfikakis, Francesco La Torre, Andrea HinojosaAzaola, Eduardo MartínNares , Jiram TorresRuiz, Gafaar Ragab, Maria Cristina Maggio, Joanna Makowska, Emanuela Del Giudice, Elena Bartoloni , Giacomo Emmi , Marcello Govoni, Alberto Lo Gullo , Giuseppe Lopalco, Gabriele Simonini, Lampros Fotis, Benson Ogunjimi, Samar Tharwat, Bruno Frediani, Armin Maier, Francesco Carubbi , Lorenzo Dagna, Sukran Erten, Antonio Gidaro, José HernándezRodríguez, Paolo Sfriso , Claudia Fabiani, Roberto Giacomelli, Luca Cantarini 2,3 To cite: Ruscitti P, Masedu F, Vitale A, et al. Derivation and validation of four patient clusters in Still’s disease, results from GIRRCS AOSDstudy group and Imaging:Article Title: The Systemic Score May Identify Life-Threatening Evolution in Still Disease: Data from the GIRRCS AOSD-Study Group and the AIDA Network Still Disease Registry. Article Snippet: Piero Ruscitti, Francesco Masedu, Antonio Vitale, Valeria Caggiano, Ilenia Di Cola, Paola Cipriani, Marco Valenti, Henrique A Mayrink Giardini, Isabele Parente de Brito Antonelli, Marilia Ambiel Dagostin, Giuseppe Lopalco, Florenzo Iannone, Morrone Maria, Ibrahim A Almaghlouth, Kazi Nur Asfina, Hebatallah Hamed Ali, Francesco Ciccia, Daniela Iacono, Ilenia Pantano, Daniele Mauro, Petros P Sfikakis, Maria Tektonidou, Katerina Laskari, Onorina Berardicurti, Lorenzo Dagna, Alessandro Tomelleri, Abdurrahman Tufan, Rıza Can Kardas, Andrea Hinojosa-Azaola, EduardoMartín-Nares, Perla Ayumi Kawakami-Campos, Gaafar Ragab, Mohamed Tharwat Hegazy, Haner Direskeneli, Fatma Alibaz-Oner, Lampros Fotis, Paolo Sfriso, Marcello Govoni, Francesco La Torre, Maria Cristina Maggio, Carlomaurizio Montecucco, Ludovico De Stefano, Serena Bugatti, Silvia Rossi, Joanna Makowska, Emanuela Del Giudice, Giacomo Emmi, Elena Bartoloni, José Hern andez-Rodríguez, Giovanni Conti, Alma Nunzia Olivieri, Alberto Lo Gullo, Gabriele Simonini, Ombretta Viapiana, Ewa Wiesik-Szewczyk, Sukran Erten, Francesco Carubbi, Amato De Paulis, Armin Maier, Samar Tharwat, Stefania Costi, Annamaria Iagnocco, Gian Domenico Sebastiani, Antonio Gidaro, Antonio Luca Brucato, Anastasios Karamanakos, Nurullah Akkoç, Francesco Caso, Luisa Costa, Marcella Prete, Federico Perosa, Fabiola Atzeni, Giuliana Guggino, Claudia Fabiani, Bruno Frediani, Roberto Giacomelli, and Luca Cantarini other:Article Title: The administration of methotrexate in patients with Still's disease, "real-life" findings from AIDA Network Still Disease Registry. Article Snippet: Methods: Patients with Still’s disease treated with MTX were assessed among those included in Article Title: The administration of methotrexate in patients with Still's disease, "real-life" findings from AIDA Network Still Disease Registry. Article Snippet: Study design, patients, and settings Patients with Still’s disease treated with MTX were selected among those included in the |